Walgreens Boots Alliance Flis 24% On Better Than Expected Q1 Earnings, Sticks To Annual Profit Forecast
Walgreens Boots Alliance Flis 24% On Better Than Expected Q1 Earnings, Sticks To Annual Profit Forecast
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.On Friday, $Walgreens Boots Alliance (WBA.US)$ reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the consensus of $37.28 billion, reflecting sales growth across all segments.
星期五， $沃爾格林-聯合博姿 (WBA.US)$ 報告第一季度銷售額爲394.6億美元，同比增長7.5%（以固定貨幣計算同比增長6.9%），超過372.8億美元的預期，反映了所有板塊的銷售增長。
Adjusted operating income was $593 million compared to adjusted operating income of $687 million in the year-ago quarter, reflecting lower U.S. retail sales and lapping prior year sale-leaseback gains, partly offset by cost savings initiatives and growth in the U.S. Healthcare segment.
調整後的營業收入爲59300萬美元，而去年同期的調整後營業收入爲68700萬美元，反映出美國零售銷售下降以及去年銷售-租回收益的對比 effect，部分被成本節約措施和美國醫療保健板塊的增長抵消。
Adjusted EPS was $0.51, down from $0.66 a year ago, beating the consensus of $0.37, according to data from Benzinga Pro.
調整後的每股收益爲0.51美元，低於去年同期的0.66美元，但超出0.37美元的預期，根據Benzinga Pro的數據。
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.
美國零售藥房板塊的銷售額達到309億美元，增長6.6%。可比銷售增長8.5%。
Pharmacy sales increased by 10.4%, and comparable pharmacy sales increased by 12.7%, driven by higher branded drug inflation and prescription volume.
藥房銷售增長了10.4%，可比藥房銷售增長了12.7%，主要受品牌藥品通脹和處方成交量增加的推動。
Comparable prescriptions increased by 2.3%, and prescriptions excluding immunizations increased by 3.5% compared to a year ago.
可比處方增加了2.3%，不包括免疫接種的處方則增加了3.5%，與去年相比。
Total prescriptions filled in the quarter, including immunizations, increased 1.5% to 316.3 million.
包括免疫接種在內的季度內總處方量增加了1.5%，達31630萬。
Retail sales decreased 6.2%, and comparable retail sales decreased 4.6% compared with the year-ago quarter, mirroring a weaker cough cold flu season and lower sales in discretionary categories.
零售銷售下降了6.2%，可比零售銷售較去年同期下降了4.6%，反映出寒冷流感季節較弱以及可自由支配類商品銷售降低。
The U.S. Healthcare segment's sales were $2.2 billion. VillageMD sales increased 9%, CareCentrix sales increased 16%, and Shields sales rose 30%.
美國醫療保健部門的銷售額爲22億。VillageMD的銷售額增長了9%，CareCentrix的銷售額增長了16%，Shields的銷售額增長了30%。
Walgreens Boots Alliance maintains fiscal 2025 adjusted EPS guidance of $1.40 – $1.80 versus the consensus of $1.52.
沃爾格林-聯合博姿維持2025財年的每股收益調整指引爲1.40美元至1.80美元，而市場共識爲1.52美元。
The company expects growth in U.S. Healthcare and International offset by pressure in U.S. Retail Pharmacy largely driven by weaker retail front end performance.
公司預計美國醫療保健和國際業務的增長將被美國零售藥房的壓力所抵消，後者主要受到零售前端表現疲弱的影響。
